Cipher Pharmaceuticals Inc (CPH) - Total Assets

Latest as of March 2026: CA$153.39 Million CAD ≈ $110.96 Million USD

Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) holds total assets worth CA$153.39 Million CAD (≈ $110.96 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Cipher Pharmaceuticals Inc to assess how comfortably operating cash covers total debt obligations.

Cipher Pharmaceuticals Inc - Total Assets Trend (2004–2025)

This chart illustrates how Cipher Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See CPH net asset value for net asset value and shareholders' equity analysis.

Cipher Pharmaceuticals Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

Cipher Pharmaceuticals Inc's total assets of CA$153.39 Million consist of 17.9% current assets and 82.1% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$7.49 Million 4.8%
Accounts Receivable CA$11.19 Million 7.2%
Inventory CA$8.18 Million 5.2%
Property, Plant & Equipment CA$569.00K 0.4%
Intangible Assets CA$71.88 Million 46.0%
Goodwill CA$17.42 Million 11.2%

Asset Composition Trend (2004–2025)

This chart illustrates how Cipher Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Cipher Pharmaceuticals Inc.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Cipher Pharmaceuticals Inc's current assets represent 17.9% of total assets in 2025, a decrease from 76.3% in 2004.
  • Cash Position: Cash and equivalents constituted 4.8% of total assets in 2025, down from 46.5% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 0.0% in 2004.
  • Asset Diversification: The largest asset category is intangible assets at 46.0% of total assets.

Cipher Pharmaceuticals Inc Competitors by Total Assets

Key competitors of Cipher Pharmaceuticals Inc based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
China CN¥11.80 Billion
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
China CN¥3.12 Billion

Cipher Pharmaceuticals Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.25 2.28 2.42
Quick Ratio 0.85 1.97 2.29
Cash Ratio 0.00 1.25 0.00
Working Capital CA$5.13 Million CA$22.56 Million CA$14.27 Million

Cipher Pharmaceuticals Inc - Advanced Valuation Insights

This section examines the relationship between Cipher Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.32
Latest Market Cap to Assets Ratio 1.98
Asset Growth Rate (YoY) -3.9%
Total Assets CA$156.22 Million
Market Capitalization $309.13 Million USD

Valuation Analysis

Above Book Valuation: The market values Cipher Pharmaceuticals Inc's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.

Slight Asset Contraction: Cipher Pharmaceuticals Inc's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Cipher Pharmaceuticals Inc (2004–2025)

The table below shows the annual total assets of Cipher Pharmaceuticals Inc from 2004 to 2025.

Year Total Assets Change
2025-12-31 CA$156.22 Million
≈ $113.01 Million
-3.87%
2024-12-31 CA$162.51 Million
≈ $117.56 Million
+88.90%
2023-12-31 CA$86.03 Million
≈ $62.23 Million
+16.61%
2022-12-31 CA$73.78 Million
≈ $53.37 Million
+42.84%
2021-12-31 CA$51.65 Million
≈ $37.36 Million
+16.66%
2020-12-31 CA$44.28 Million
≈ $32.03 Million
-4.69%
2019-12-31 CA$46.45 Million
≈ $33.60 Million
-16.58%
2018-12-31 CA$55.69 Million
≈ $40.28 Million
-11.79%
2017-12-31 CA$63.13 Million
≈ $45.67 Million
-18.44%
2016-12-31 CA$77.41 Million
≈ $55.99 Million
-29.40%
2015-12-31 CA$109.65 Million
≈ $79.32 Million
+884.67%
2014-12-31 CA$11.14 Million
≈ $8.06 Million
-78.66%
2013-12-31 CA$52.17 Million
≈ $37.74 Million
+136.40%
2012-12-31 CA$22.07 Million
≈ $15.96 Million
+53.71%
2011-12-31 CA$14.36 Million
≈ $10.39 Million
-11.21%
2010-12-31 CA$16.17 Million
≈ $11.70 Million
+14.23%
2009-12-31 CA$14.16 Million
≈ $10.24 Million
+5.20%
2008-12-31 CA$13.46 Million
≈ $9.73 Million
-28.80%
2007-12-31 CA$18.90 Million
≈ $13.67 Million
-2.11%
2006-12-31 CA$19.31 Million
≈ $13.97 Million
-12.78%
2005-12-31 CA$22.14 Million
≈ $16.02 Million
-31.59%
2004-12-31 CA$32.36 Million
≈ $23.41 Million
--

About Cipher Pharmaceuticals Inc

TO:CPH Canada Drug Manufacturers - Specialty & Generic
Market Cap
$309.13 Million
CA$427.34 Million CAD
Market Cap Rank
#14528 Global
#431 in Canada
Share Price
CA$16.83
Change (1 day)
+2.25%
52-Week Range
CA$12.85 - CA$19.74
All Time High
CA$19.74
About

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more